PatternsRadar
Sign in

ZOTAZota Health Care LImited

NSE
Full chart
1,278.60INR-18.80 (-1.45%)Close · 6 Oct 2026
13 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹4,428 CrMarket cap
—P/E (TTM)
54.1%Delivery

Filings & corporate actions

27 results filed
CSV
Next results · Q2 FY27
Expected 17 Oct 2026 – 15 Nov 2026
Estimate: filed 17–46 days after quarter end, last 5 times
Dividend
₹1.00 per share · last 21 Sept 2026
2026
  • 21 SeptdividendDividend · ₹1.00 per share+12.5%
  • 13 AugresultsResults · Q1 FY27 · consolidated and standalone-8.9%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026-1.4%NSE
  • 22 MayresultsResults · Q4 FY26 · consolidated and standalone-5.9%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026+0.4%NSE
  • 4 FebresultsResults · Q3 FY26 · consolidated and standalone-2.6%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-5.2%NSE

Reaction to results · all yearsrose on day 0 in 11 of 27 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2713 Aug 2026-8.9%-12.4%-12.4%8.0×
Q4 FY2622 May 2026-5.9%-4.1%+15.4%4.1×
Q3 FY264 Feb 2026-2.6%+6.1%-9.8%0.5×
Q2 FY2617 Oct 2025+2.7%+3.0%+8.3%1.6×
Q1 FY268 Aug 2025+0.1%+11.6%+24.7%1.1×
Q4 FY2529 May 2025+0.2%-5.5%-1.3%0.5×
Q3 FY2514 Feb 2025-3.7%-5.7%-13.2%0.4×
Q2 FY2515 Nov 2024-1.7%-1.3%+33.7%1.3×
Q1 FY2514 Aug 2024+1.0%+7.9%+4.2%0.3×
Q4 FY2430 May 2024-0.9%+7.7%+20.9%0.8×
Q3 FY249 Feb 2024-0.8%-3.3%+2.4%0.4×
Q2 FY2411 Nov 2023+1.9%-1.6%+17.6%0.8×
Q1 FY2414 Aug 2023+7.4%+2.5%-11.4%6.3×
Q4 FY2331 May 2023-0.4%+7.0%+30.0%0.7×
Q2 FY2314 Nov 2022+3.1%+0.3%0.0%0.7×
Q1 FY2313 Aug 2022-0.5%-4.2%+14.7%0.6×
Q4 FY2231 May 2022-1.9%-7.3%-7.0%0.5×
Q3 FY2212 Feb 2022-3.4%-16.4%-16.4%1.2×
Q2 FY221 Nov 2021-2.0%-2.3%+4.9%0.8×
Q1 FY2231 Jul 2021+20.0%+40.9%+53.9%13.3×
Q4 FY2126 Jun 2021-1.8%+19.2%+25.6%0.6×
Q3 FY2111 Feb 2021-0.3%+0.2%-2.1%0.2×
Q2 FY2112 Nov 2020+0.1%+0.6%+9.0%0.6×
Q1 FY2126 Aug 2020+3.1%-6.1%-6.4%6.4×
Q4 FY2024 Jun 2020-1.0%-4.9%-4.2%0.4×
Q3 FY208 Feb 2020+1.9%-3.5%-12.2%1.0×
Q2 FY2015 Nov 2019-1.1%-2.0%+0.9%1.0×
Average+0.2%+1.0%+6.3%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+67.6%
Profit YoY—
Interest cost YoY+84.1%
Revenue QoQ+6.4%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+75.3%—+48.0%+37.8%+37.3%—
Profit——————

Key data

CSV
Open1,297.00
Day range1,275.00 – 1,305.00
52-week range1,022.00 – 1,740.00
From 52w high-26.5%
RSI (14)56.8
ATR (14)56.47
Volume20.1K
Avg volume (20D)1.28L
Rel volume0.16×
Volatility (1Y)43.8%
Turnover₹2.6Cr
SMA 50 / 2001,190.03 / 1,274.99

Delivery percentage

Latest · 6 Oct 202654.1%
20-day avg54.8%
1-year avg55.1%
Percentile (own history)50th
Range0.6–99.9%
Sessions1,731

Over the last 20 sessions ZOTA settled 54.8% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 55.1%. The latest session ranks higher than 50% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-1.45%-3.30%+16.11%-8.78%+15.14%-10.57%

Valuation

CSV
Market cap₹4,428 Cr
P/E (TTM)—
EPS (TTM)-30.10
Shares outstanding3.46Cr
Listed19 Aug 2019

Ownership

CSV
Promoter49.38%
Promoter Δ QoQ0.00 pp
Public50.62%
FII7.92%
DII6.75%
Pledged0.26%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)128.9143.0163.2173.6
YoY chg+91.7%+98.2%+67.7%+67.6%
Net profit (₹ Cr)(16.2)(29.6)(14.5)(43.9)
YoY chg————
Net margin-12.6%-20.7%-8.9%-25.3%
EPS-5.02-9.21-4.13-12.58

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 49.38% · public 50.62%
30 Sept 2021: promoter 68.10%31 Dec 2021: promoter 68.09%31 Mar 2022: promoter 68.11%30 Jun 2022: promoter 68.12%30 Sept 2022: promoter 68.12%31 Dec 2022: promoter 68.12%31 Mar 2023: promoter 68.12%30 Jun 2023: promoter 68.12%18 Jul 2023: promoter 66.16%30 Sept 2023: promoter 66.16%31 Dec 2023: promoter 66.15%31 Mar 2024: promoter 66.15%6 Apr 2024: promoter 64.45%30 Jun 2024: promoter 64.44%14 Aug 2024: promoter 62.40%30 Sept 2024: promoter 62.40%31 Dec 2024: promoter 62.02%20 Feb 2025: promoter 59.72%31 Mar 2025: promoter 59.72%17 Apr 2025: promoter 58.11%30 Jun 2025: promoter 57.42%30 Sept 2025: promoter 55.81%17 Dec 2025: promoter 51.56%31 Dec 2025: promoter 50.64%31 Mar 2026: promoter 49.38%30 Jun 2026: promoter 49.38%
2021-092026-06
  • Promoter
  • Public and others
Promoter
49.38%
Public
50.62%
Promoter change
0.00 pp
Filed
20 Jul 2026
FII
7.92%
DII
6.75%
Promoter pledged
0.26%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations45.346.949.656.367.372.197.3103.6128.9143.0163.2173.6
Other income0.40.20.50.00.50.51.00.91.61.73.22.0
Total income45.747.150.156.367.872.698.3104.5130.6144.7166.4175.6
Total expenses46.849.859.668.580.591.1112.6117.5145.0170.6186.8219.3
└ Finance costs1.11.11.72.92.91.63.53.23.85.05.36.4
└ Depreciation4.85.16.88.09.511.314.314.718.522.327.027.7
Profit before tax(1.1)(2.7)(9.5)(12.2)(12.7)(18.5)(14.3)(13.1)(14.4)(26.0)(26.4)(43.7)
Tax expense0.50.2(2.6)0.6(0.5)0.5(1.4)0.71.83.7(12.0)0.3
Net profit(1.7)(2.9)(6.9)(12.7)(12.2)(18.9)(12.9)(13.8)(16.2)(29.6)(14.5)(43.9)
EPS-0.64-1.14-2.68-4.80-4.57-6.80-4.57-4.92-5.26-9.44-4.13-12.58
Net margin-3.65%-6.26%-13.94%-22.60%-18.11%-26.27%-13.25%-13.30%-12.56%-20.74%-8.86%-25.31%
PBT margin-2.46%-5.82%-19.16%-21.60%-18.87%-25.63%-14.71%-12.63%-11.15%-18.15%-16.19%-25.15%
Tax rate————————————

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 13 Aug 2026.

ZOTA at a glance

  • ZOTA closed at ₹1,278.6 on 6 Oct 2026, -1.45% on the day, -10.6% over one year, 26.5% below its 52-week high of ₹1,740.
  • Delivery was 54.1% of traded quantity on 6 Oct 2026, the 50th percentile of its own 1,731 sessions with a reading (20-session average 54.8%, 1-year average 55.1%).
  • Market capitalisation is ₹4,428 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-30.1).
  • Q1 FY27 results (consolidated, filed 13 Aug 2026): revenue ₹174 crore (+67.6% year on year), net profit ₹-44 crore; the price moved -8.9% on the first session after.
  • Promoters held 49.38% at 30 Jun 2026, unchanged on the previous filing, with 0.26% of promoter shares pledged.
  • Q2 FY27 results are expected between 17 Oct 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE358U01012
SeriesEQ
Listed19 Aug 2019
History from10 May 2017
Sessions2,329
Turnover rank#857

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE